A Monumental $128 Million Step Forward for HHT Research

Today is a monumental day for HHT. The new biotechnology company, Diagonal Therapeutics, officially launched and we wanted to share more about why this is news you simply can’t miss!

In short, Diagonal’s lead program is focused on developing an innovative treatment not just to alleviate the symptoms of HHT – but using antibodies to reverse the formation of vascular malformations altogether. That’s right, there is now a biotechnology company, backed by $128 million in Series A financing, focused entirely on a curative HHT therapy.

For months, Cure HHT has been collaborating with Diagonal’s management team to help make this day a reality. We have connected them to leading HHT scientists to help them further develop their program, and have spent countless hours meeting with venture capital firms to educate them on the burden of this disease and help Diagonal secure funding to launch.

“Cure HHT is so much more than a patient advocacy organization. Nearly two years ago, our organization invested in creating a Therapeutic Development Arm, bringing the necessary talent in house to help us proactively bring forward promising therapies to patients faster. We are not sitting on the sideline and hoping change comes. We are rolling up our sleeves and making it happen. A day like today is a significant milestone for our disease, and represents a reason for our patient community to have hope!”

– Marianne Clancy, Executive Director, Cure HHT

Diagonal’s Groundbreaking Approach

Diagonal’s pioneering approach harnesses the power of agonist antibodies going beyond symptom management to potentially alter the disease’s trajectory by reactivating the body’s natural healing pathways. With a blend of bold innovation and technological prowess, Diagonal is setting a new standard for what’s possible in treating HHT.

Going beyond symptom management: Addressing HHT at its very roots, potentially altering the disease’s trajectory by focusing on reactivating the body’s natural pathways towards healing.
Innovative DIAGONAL Platform: The DIAGONAL platform combines advanced computational techniques with experimental science, swiftly pinpointing effective treatments, turning possibility into reality.
Precise Therapies: Diagonal’s treatments are designed to specifically target HHT and are crafted to target specific biological signals, minimizing side effects and maximizing potential benefits.

Click here to learn more about Diagonal Therapeutics and their groundbreaking approach.

Cure HHT’s Influence in Action

From initial engagements in 2022 to ongoing partnerships, Cure HHT has worked to steer Diagonal’s focus towards HHT. Our Executive Director, Marianne Clancy, was instrumental in partnering with Diagonal Therapeutics to invest in a future where HHT is a treatable condition. Our journey and conversations have culminated in one of the most influential wins in our history, funding the advancement of Diagonal’s lead program for HHT treatment and expanding efforts to include pulmonary arterial hypertension (PAH).

Unprecedented Funding for Unprecedented Progress

This significant funding is not just a testament to Diagonal’s potential, it’s a validation of our shared vision for a better future in HHT treatment. Together, we’ve sparked a transformation in HHT research and therapy development, proving that our collective voice is influential and heard. It’s more than just funding – it is a resounding vote of confidence in our ability to revolutionize HHT treatment.

What This Means for Our Community

Diagonal’s impactful launch and groundbreaking approach shines a light on HHT like never before. This step forward was made possible by our collective support, passion, and steadfast pursuit of innovation. It’s a direct result of our efforts and your support — a true example of how we’re catalyzing change for HHT. Join us in celebrating the monumental win!

Explore more about Diagonal Therapeutics and the promising impact of their work. This is a victory for us all, and together, we’ll continue pushing for advancements that truly make a difference.

Stay Informed